文献速递头颈部肿瘤放疗胸部肿瘤放疗消化道肿瘤放疗

跨癌种分析揭示根治性放疗期间独特的免疫调节模式

Cross-Cancer Analysis Reveals a Distinct Pattern of Immune Modulation During Curative Radiation Therapy.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2025-09-19

结果显示放疗后趋化因子CXCL12和MCP-1升高,单核细胞增加而NK细胞和B细胞减少;发生远处转移的患者循环CD4效应T细胞显著下降。

要点

  • 根治性放疗后单核细胞增加、NK细胞和B细胞减少。
  • CXCL12和MCP-1在放疗后显著升高,与单核细胞变化一致。
  • 发生远处转移者CD4效应T细胞下降,未复发者无变化。

核心结论

  • 根治性放疗后出现跨癌种保守的免疫改变,表现为促肿瘤髓系细胞增加、B细胞和NK细胞减少,且远处转移者CD4效应T细胞显著下降。

研究设计与样本

  • 放疗前和放疗45 Gy后采血,用多重Luminex细胞因子检测和高维质谱流式(CyTOF)分析免疫变化。

主要发现

  • 中位随访21个月,出现3例局部复发和12例远处转移。
  • 放疗后CXCL12升高(P=.044),MCP-1升高(P<.001)。
  • 放疗后单核细胞增加(P<.001),NK细胞和B细胞减少(P<.001)。
  • 发生远处转移者循环CD4效应T细胞下降(P=.049),未复发者无变化。
  • 上述免疫改变与肿瘤类型和是否同步化疗无关。

关键数值与推荐

  • 根治性放疗剂量>45 Gy,分次1.8-3 Gy。
  • 约50%患者接受同步化疗。
  • 放疗后CXCL12 P=.044,MCP-1 P<.001,单核细胞P<.001,NK/B细胞P<.001,CD4效应T细胞P=.049。

临床怎么用

  • 放疗期间可监测循环单核细胞、NK细胞、B细胞及CD4效应T细胞变化以评估免疫状态。
  • 对CD4效应T细胞下降者应警惕远处转移风险,但需进一步验证。

局限性

  • 约50%患者接受同步化疗,可能混杂免疫分析。
  • 免疫改变与结局的关联需更大样本验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Radiation therapy (RT) is a cornerstone of curative cancer treatment, yet its immune effects are not fully understood. This study examined systemic immune profile changes in patients undergoing RT for solid tumors. METHODS AND MATERIALS: Patients with localized head and neck cancer, non-small cell lung cancer, rectal cancer, or extremity soft tissue sarcoma treated with curative RT (>45 Gy, 1.8-3 Gy/fraction) were enrolled. Baseline and post-RT (after 45 Gy) blood samples were analyzed using multiplex Luminex cytokine assays and high-dimensional mass cytometry (cytometry by time-of-flight). Immune alterations were correlated with patient outcomes. RESULTS: Thirty-seven patients treated with curative RT for head and neck cancer (n = 8), non-small cell lung cancer (n = 8), rectal cancer (n = 7) or soft tissue sarcoma (n = 14) were enrolled. Approximately 50% of patients received concurrent chemotherapy. At a median follow-up of 21 months, there were 3 local and 12 distant recurrences. Cytokine analysis showed increased C-X-C motif chemokine ligand 12 (P = .044) and monocyte chemoattractant protein-1 (P < .001), both important in monocyte trafficking and mobilization. Consistent with the cytokine changes, cytometry by time-of-flight demonstrated increased monocytes (P < .001) and reduced natural killer and B cells (P < .001). Circulating CD4 effector T cells decreased in patients who developed distant metastases (P = .049) but remained unchanged in recurrence-free patients. These effects were independent of tumor type and chemotherapy, indicating conserved immune changes following RT. CONCLUSIONS: We identified a distinct pattern of immune change across all tumor types analyzed in response to RT, with increases in protumoral myeloid cell populations, reductions in B cells and natural killer cells, and a significant decrease in CD4 effector T cells among patients who developed distant metastases.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Said BI, Boukhaled GM, Lok BH, et al. Cross-Cancer Analysis Reveals a Distinct Pattern of Immune Modulation During Curative Radiation Therapy. Int J Radiat Oncol Biol Phys. 2025. PMID: 40970850. doi:10.1016/j.ijrobp.2025.08.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。